Textbook of Bone Metastases
John Wiley & Sons Inc (Verlag)
978-0-471-87742-4 (ISBN)
- Titel ist leider vergriffen;
keine Neuauflage - Artikel merken
The epidemiological and clinical importance of bone metastases has long been recognised. For example, the incidence of bone metastases in breast and prostate cancers is 70 per cent, whereas it is only 30 to 40 per cent in metastatic lung cancer. In clinical terms, bone metastases have substantial negative effects on the patient's quality of life. Bone metastases have generally received insufficient attention because of the difficulty in quantifying them, which has left them outside the scope of therapeutic trials. This textbook is the result of the remarkable progress made in the understanding of the molecular and cellular mechanisms involved in osteogenesis and osteolysis, and their development for therapeutic purposes. The treatment of malignant hypercalcaemia has also been revolutionised by the use of bisphosphonates. "The Textbook of Bone Metastases" presents a broad approach to recent progress in all fields related to bone metastases, ranging from epidemiology to the physiopathology of bone metastases and therapeutics.
It provides a better understanding of recent advances and, more importantly, will give clinicians all the information needed to help them in the clinical and therapeutic management of patients with bone metastases.
Claude Jasmin is the editor of Textbook of Bone Metastases, published by Wiley. Rodolfo Capanna is the editor of Textbook of Bone Metastases, published by Wiley. Lawrence Coia is the editor of Textbook of Bone Metastases, published by Wiley. Robert Coleman is the editor of Textbook of Bone Metastases, published by Wiley. Gerard Saillant is the editor of Textbook of Bone Metastases, published by Wiley.
Contributors Preface. SECTION 1: BIOLOGY OF BONE METASTASES (R. Coleman). 1. General mechanisms of metastasis (S. Eccles). 2. Parathyroid hormone-related Protein and Bone metastases (T. Martin, et al.). 3. Osteoblastic Metastases (P. Croucher). 4. The Role of RANK, RANK Ligand and Osteoprotegerin in the Lytic Effects and Growth of Bone Metastases (C. Dunstan). SECTION 2: CLINICAL FEATURES AND ASSESSMENT (R. Coleman). 5. Clinical Features and Prognosis of Bone Metastases (T. Plunkett & R. Rubens). 6. Radio-isotope and PET Imaging of Bone Metastases (G. Cook & I. Fogelman). 7. Imaging of Spinal Bone Metastases (R. Guillevin, et al.). 8. Monitoring Response to Treatment - the Role of Biochemical Markers (R. Coleman & J. Brown). 9.Surgical Biopsy of Bone Metastases (M. Salai & I. Dudliewicz). SECTION 3: SURGICAL TREATMENT (R. Capanna). 10. Indications for the Surgical Treatment of Long Bone Metastases (R. Capanna & D. Campanacci). 11. Prosthetic Replacement in Long Bone Metastases (B. Fuchs, et al.). 12. Osteosynthesis for Pathological Fractures in Long Bones (P. Dijksta & A. Taminiau). 13. Surgical Treatment of Pelvic Metastases (R. Windhager). 14. Indications and Strategy for the Treatment of Spinal Metastases (E. Enkaoua). 15. Surgical Techniques for the Treatment of Bone Metastases of the Spine (S.Boriani) . 16. Total En Bloc Spondylectomy for Spinal Metastases (N. Kawahara, et al.). SECTION 4: LOCAL TREATMENTS (L. Coia). 17. External Beam Radiation Therapy for the Treatment of Bone Metastases - (P. Anderson & L. Coia) . 18. Interventional Radiology for Bone Metastases (J. Chiras, et al.). 19. Percutaneous Injection of Ethanol (A. Cotten & L. Ceugnari). SECTION 5: SYSTEMIC TREATMENTS (C. Jasmin). 20. Chemotherapy - (M. Green & G. Hortobagyi). 21. Endocrine Treatment of Bone Metastases (S. Agelaki & V. Georgoulias). 22. Overview of Osteoclast Inhibitors (J. Body). 23. Radioisotopes and Radioimmunoisotopes (I. Resche, et al.). 24. Immunotherapy (T. Plunkett & D. Miles). SECTION 6: BISPHOSPHONATES (R. Coleman). 25. Mechanisms of Action of Bisphosphonates (M. Rogers). 26. Antitumor Effects of Bisphosphonates (P. Clezardin). 27. Management of Hypercalcaemia (S. Ralston). 28. Treatment of Lytic Bone Metastases (K. Gwyn & R. Theriault). 29. Use in Multiple Myeloma (J. Berenson). 30. Use in Prostate Cancer (R. Coleman). 31. Prevention of Bone Metastases (R. Coleman &H. Neville-Webbe). 32 Prevention of Bone Loss (R. Ashford, et al.). 33. Cost Implications of Bisphosphonates (E. McCloskey, et al.). SECTION 7: THE GLOBAL APPROACH (C. Jasmin). 34. Treatment of Bone Pain (D. Lossignol). 35. Specific Approaches to Cancer in the Elderly (L. Balducci). 36. Psychological and Social Aspects (O. Gilbar). 37. Metabolic Bone Diseases in Childhood Cancer (V. Tillman, et al.). SECTION 8: BONE METASTASES IN SPECIFIC TUMOURS (L. Coia). 38. Breast Cancer (W. Hartsell). 39. Prostate Cancer (E. Chow, et al.). 40. Multiple Myeloma (R. Kyle). 41. Malignant Non-Hodgkin's Lymphoma (O. Reman). 42. Lung Cancer (D. Roos). 43. Kidney Cancer (U Malik & M. Mohiuddin). 44. Evaluation of the Patient with Bone Metastases at Presentation (P. Hoskin). Index.
Erscheint lt. Verlag | 1.3.2005 |
---|---|
Verlagsort | New York |
Sprache | englisch |
Maße | 196 x 256 mm |
Gewicht | 1506 g |
Einbandart | gebunden |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie |
ISBN-10 | 0-471-87742-5 / 0471877425 |
ISBN-13 | 978-0-471-87742-4 / 9780471877424 |
Zustand | Neuware |
Haben Sie eine Frage zum Produkt? |
aus dem Bereich